Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218705 · ClinicalTrials.gov registry record
A Study Of MCG In Cardiac Amyloidosis
A clinical trial of Amyloidosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT07218705: Recruiting study of Amyloidosis, sponsored by Mayo Clinic.
NCT07218705 is a study of Amyloidosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 500 participants, below the 1,111-participant average among 28 other Amyloidosis trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218705, a study of Amyloidosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.
Primary Outcome
Receiver Operating Characteristic (ROC) curve is used to compare true positive rate vs false positive rate. This will be used to determine the sensitivity, specificity, and overall effectiveness of MCG.
Conditions Studied
Interventions
- DEVICE SandboxAQ CardiAQ Magnetocardiography
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2027-11 |
What NCT07218705 shows while recruiting
NCT07218705 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,111-participant average among 28 other Amyloidosis trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which SandboxAQ CardiAQ Magnetocardiography is the first listed.
NCT07218705 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07218705 about?
NCT07218705 is a clinical study titled "A Study Of MCG In Cardiac Amyloidosis". The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.
What is the current status of trial NCT07218705?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-12-03. Estimated completion is 2027-11.
What conditions does trial NCT07218705 study?
This clinical trial studies the following conditions: Amyloidosis.
What interventions are being tested in trial NCT07218705?
The interventions under investigation include: SandboxAQ CardiAQ Magnetocardiography (DEVICE).
Who is sponsoring clinical trial NCT07218705?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218705 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07218705's enrollment target sits among peer trials
500 7th of 28 higher than 22 of 28 other Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI